These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 9377612)
1. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Fish JE; Kemp JP; Lockey RF; Glass M; Hanby LA; Bonuccelli CM Clin Ther; 1997; 19(4):675-90. PubMed ID: 9377612 [TBL] [Abstract][Full Text] [Related]
2. An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses. Tashkin DP; Nathan RA; Howland WC; Minkwitz MC; Simonson SG; Bonuccelli CM J Allergy Clin Immunol; 1999 Feb; 103(2 Pt 1):246-54. PubMed ID: 9949315 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of Zafirlukast ('Accolate') in the management of patients with mild-to-moderate asthma. Chukwu C; Okpapi J; Ige MO; Obodo JO West Afr J Med; 2000; 19(2):111-9. PubMed ID: 11070746 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Suissa S; Dennis R; Ernst P; Sheehy O; Wood-Dauphinee S Ann Intern Med; 1997 Feb; 126(3):177-83. PubMed ID: 9027267 [TBL] [Abstract][Full Text] [Related]
6. Effects of adding a leukotriene antagonist or a long-acting beta(2)-agonist in asthmatic patients with the glycine-16 beta(2)-adrenoceptor genotype. Lipworth BJ; Dempsey OJ; Aziz I; Wilson AM Am J Med; 2000 Aug; 109(2):114-21. PubMed ID: 10967152 [TBL] [Abstract][Full Text] [Related]
7. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. Busse W; Wolfe J; Storms W; Srebro S; Edwards L; Johnson M; Bowers BW; Rogenes PR; Rickard K J Fam Pract; 2001 Jul; 50(7):595-602. PubMed ID: 11485708 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness and tolerability of zafirlukast for the treatment of asthma in children. Pearlman DS; Lampl KL; Dowling PJ; Miller CJ; Bonuccelli CM Clin Ther; 2000 Jun; 22(6):732-47. PubMed ID: 10929920 [TBL] [Abstract][Full Text] [Related]
9. Zafirlukast in clinical practice: results of the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT) in patients with asthma. Kemp JP; Korenblat PE; Scherger JE; Minkwitz M J Fam Pract; 1999 Jun; 48(6):425-32. PubMed ID: 10386485 [TBL] [Abstract][Full Text] [Related]
10. An open study to evaluate the safety and efficacy of zafirlukast ("Accolate") in patients with mild to moderate asthma in Ibadan, Nigeria. Ige OM; Onadeko BO West Afr J Med; 2001; 20(4):220-6. PubMed ID: 11885876 [TBL] [Abstract][Full Text] [Related]
11. Two first-line therapies in the treatment of mild asthma: use of peak flow variability as a predictor of effectiveness. Nathan RA; Minkwitz MC; Bonuccelli CM Ann Allergy Asthma Immunol; 1999 May; 82(5):497-503. PubMed ID: 10353583 [TBL] [Abstract][Full Text] [Related]
12. Therapeutic effect of zafirlukast as monotherapy in steroid-naive patients with severe persistent asthma. Kemp JP; Minkwitz MC; Bonuccelli CM; Warren MS Chest; 1999 Feb; 115(2):336-42. PubMed ID: 10027429 [TBL] [Abstract][Full Text] [Related]
13. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Virchow JC; Prasse A; Naya I; Summerton L; Harris A Am J Respir Crit Care Med; 2000 Aug; 162(2 Pt 1):578-85. PubMed ID: 10934090 [TBL] [Abstract][Full Text] [Related]
14. Comparison of inhaled salmeterol and oral zafirlukast in asthmatic patients using concomitant inhaled corticosteroids. Nelson HS; Nathan RA; Kalberg C; Yancey SW; Rickard KA MedGenMed; 2001 Jul; 3(4):3. PubMed ID: 11549982 [TBL] [Abstract][Full Text] [Related]
15. Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials. Barnes NC; Miller CJ Thorax; 2000 Jun; 55(6):478-83. PubMed ID: 10817796 [TBL] [Abstract][Full Text] [Related]
16. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma. Busse W; Nelson H; Wolfe J; Kalberg C; Yancey SW; Rickard KA J Allergy Clin Immunol; 1999 Jun; 103(6):1075-80. PubMed ID: 10359889 [TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of zafirlukast in the treatment of asthma: interim results of an open-label extension trial. Grossman J; Smith LJ; Wilson AM; Thyrum PT Ann Allergy Asthma Immunol; 1999 Apr; 82(4):361-9. PubMed ID: 10227334 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the effects of zafirlukast 40 mg b.i.d. in addition to preexisting therapy of high-dose inhaled steroids on symptomatic patients with reversible respiratory obstruction: preliminary data. Centanni S; Santus P; Casanova F; Di Marco F; Brazzola G; Canonica GW Drugs Exp Clin Res; 2000; 26(4):133-8. PubMed ID: 11109513 [TBL] [Abstract][Full Text] [Related]
19. Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma. Adkins JC; Brogden RN Drugs; 1998 Jan; 55(1):121-44. PubMed ID: 9463793 [TBL] [Abstract][Full Text] [Related]
20. Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT). Korenblat PE; Kemp JP; Scherger JE; Minkwitz MC; Mezzanotte W Ann Allergy Asthma Immunol; 2000 Feb; 84(2):217-25. PubMed ID: 10719780 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]